CEL SCI CORP — Director's Dealing 2021

Nov 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CEL SCI CORP (CVM)
CIK: 0000725363
Period of Report: 2021-11-19

Reporting Person: KERSTEN GEERT R (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-19	Options	$10.48	A	50000	Acquired	2031-11-18	Common Stock (50000)	Direct

Footnotes

F1: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022.